 The study will have 4 Visits, at Day 1 Visit 1, at Day 3 Visit 2, at Day 7 Visit 3 and at Day 14 Visit 4. Potentially eligible patients will be screened at Visit 1. Patients found to be eligible will be allocated to one of the two treatments etoricoxib 60 mg or 90 mg. Each patient will be treated for 14 days. Early termination of study on Visit 3 Day 7 will be possible in case of complete resolution of the symptoms. All procedures of the study must be done after the patient sign the informed consent. An ultrasound and X-ray evaluation of the affected shoulder will be done on Day 1 and haematological and biochemistry laboratory evaluation will be done on Day 1 and at the end of treatment. 